Comparison of Latanoprost and Dorzolamide in Patients with Open Angle Glaucoma

ABSTRACT

To compare the ocular hypotensive efficacy and side effects of either latanoprost or dorzolamide in patients with open angle glaucoma, forty-four patients with open angle glaucoma were included in a randomized, double masked study for a period of 3 months. All previous glaucoma medications were stopped and the patients were randomized to receive either latanoprost 0.005% at bed time or dorzolamide 2% three times daily. After 3 months, the mean reduction in rap was 6.8 (SD 3.1) mm Hg in the latanoprost group as compared to 4.7 (SD 2.4) mm Hg in the dorzolamide group. The difference of 2.1 nun Hg was highly significant. Both the drugs were well tolerated systemically and locally. Latanoprost was superior to dorzolamide in reducing the mean lOP and thus has the potential for becoming the first line treatment in glaucoma.